Source:http://linkedlifedata.com/resource/pubmed/id/10091699
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1999-5-24
|
| pubmed:abstractText |
Cinnamyl derivatives of thieno[2,3-d]oxazinones are mechanism-based inhibitors of the HSV-2, VZV and CMV herpes proteases which demonstrate nanomolar potency. Compounds 5 and 28 inhibit protease processing in HSV-2 infected cells with a selectivity index of at least 30.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0960-894X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
8
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
443-8
|
| pubmed:dateRevised |
2000-12-18
|
| pubmed:meshHeading | |
| pubmed:year |
1999
|
| pubmed:articleTitle |
Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones.
|
| pubmed:affiliation |
SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK. Richard_L_Jarvest@sbphrd.com
|
| pubmed:publicationType |
Journal Article
|